Analysts Set Metagenomi, Inc. (NASDAQ:MGX) Target Price at $16.67

Metagenomi, Inc. (NASDAQ:MGXGet Free Report) has earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $16.67.

Several research firms have weighed in on MGX. HC Wainwright increased their price objective on Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Metagenomi in a research note on Wednesday, November 20th.

View Our Latest Research Report on Metagenomi

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its holdings in Metagenomi by 105.8% in the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after purchasing an additional 173,796 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in shares of Metagenomi by 209.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after purchasing an additional 92,468 shares in the last quarter. Novo Holdings A S grew its stake in shares of Metagenomi by 3.5% in the 2nd quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock worth $7,344,000 after buying an additional 60,825 shares during the last quarter. Verition Fund Management LLC bought a new position in Metagenomi during the 3rd quarter valued at approximately $82,000. Finally, Green Alpha Advisors LLC purchased a new position in Metagenomi during the third quarter valued at $69,000.

Metagenomi Price Performance

NASDAQ MGX opened at $3.61 on Monday. Metagenomi has a 1 year low of $1.61 and a 1 year high of $12.74. The business’s 50-day moving average is $2.60 and its 200 day moving average is $3.01.

About Metagenomi

(Get Free Report

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

Read More

Analyst Recommendations for Metagenomi (NASDAQ:MGX)

Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.